Generation of Atrial-Specific Construct Using Sarcolipin Promoter-Associated CRM4 Enhancer
Reference33 articles.
1. Carlsson L, Duker G, Jacobson I (2010) New pharmacological targets and treatments for atrial fibrillation. Trends Pharmacol Sci 31(8):364–371
2. Bongianino R, Priori SG (2015) Gene therapy to treat cardiac arrhythmias. Nat Rev Cardiol 12(9):531–546
3. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA (2011) Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92(2):218–225
4. Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA, Nakai H (2006) Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 14(1):45–53
5. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16(6):1073–1080